Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Calls It Quits On Anacetrapib

Executive Summary

Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.

Advertisement

Related Content

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Inflammation A Clue Left In ACCELERATE CETP Wreckage
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel